On Tuesday, Vivani Medical Inc (NASDAQ:VANI) announced the publication of positive proof-of-concept weight loss data with OKV-119 to treat feline obesity and diabetes in the peer-reviewed BMC ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development ...

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the first patient with its device. The procedure is part of a first-in-human ...

Feb 28 (Reuters) - Vivani Medical VANI.O shares surged more than five-fold in early trading on Wednesday after the drug developer said its experimental under-the-skin drug implant helped reduce weight ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset ...

Feb 28 (Reuters) - Vivani Medical (VANI.O), opens new tab shares surged more than five-fold in early trading on Wednesday after the drug developer said its experimental under-the-skin drug implant ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

More and more people are turning to medications like Wegovy or Ozempic to lose weight–and now man’s best friend might soon benefit as well. A biotech company is currently developing a long-term ...